MYLAN-LISINOPRIL TABLET
Land: Canada
Taal: Engels
Bron: Health Canada
Productkenmerken
(SPC)
19-12-2016
Sommige documenten voor dit product zijn momenteel niet beschikbaar, u kunt een verzoek sturen naar onze klantenservice en we zullen u hiervan op de hoogte stellen zodra we ze kunnen verkrijgen.
Verzend verzoek.
Verzend verzoek.
Werkstoffen:
LISINOPRIL (LISINOPRIL DIHYDRATE)
Beschikbaar vanaf:
MYLAN PHARMACEUTICALS ULC
ATC-code:
C09AA03
INN (Algemene Internationale Benaming):
LISINOPRIL
Dosering:
5MG
farmaceutische vorm:
TABLET
Samenstelling:
LISINOPRIL (LISINOPRIL DIHYDRATE) 5MG
Toedieningsweg:
ORAL
Eenheden in pakket:
100/500
Prescription-type:
Prescription
Therapeutisch gebied:
ANGIOTENSIN-CONVERTING ENZYME INHIBITORS
Product samenvatting:
Active ingredient group (AIG) number: 0121550003; AHFS:
Autorisatie-status:
CANCELLED POST MARKET
Autorisatie datum:
2017-08-02
Productkenmerken
Page 1 of 46
PRODUCT MONOGRAPH
PR
MYLAN-LISINOPRIL
(Lisinopril Tablets, USP)
Tablets 5 mg, 10 mg and 20 mg
(Lisinopril as lisinopril dihydrate)
Angiotensin Converting Enzyme Inhibitor
Mylan Pharmaceuticals ULC
85 Advance Road
Etobicoke, ON
M8Z 2S6
Submission Control number: 192608
Date of Revision:
December 19, 2016
Page 2 of 46
_ _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY
PRODUCT
INFORMATION
................................................................................
3
INDICATIONS
AND
CLINICAL
USE
.....................................................................................
3
CONTRAINDICATIONS
..........................................................................................................
4
WARNINGS
AND
PRECAUTIONS
.........................................................................................
4
ADVERSE
REACTIONS
.........................................................................................................
11
DRUG
INTERACTIONS
.........................................................................................................
17
DOSAGE
AND
ADMINISTRATION
.....................................................................................
19
OVERDOSAGE
.......................................................................................................................
22
ACTION
AND
CLINICAL
PHARMACOLOGY
....................................................................
23
STORAGE
AND
STABILITY
.................................................................................................
26
DOSAGE
FORMS,
COMPOSITION
AND
PACKAGING ..................................................... 26
PART II: SCIENTIFIC INFORMATION
...............................................................................
27
PHARMACEUTICAL
INFORMATION
.................................................................................
27
CLINICAL
TRIALS
....................................................
Lees het volledige document
